Journal
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 10, Issue 4, Pages 354-362Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2011.11.008
Keywords
Hepatocellular Carcinoma; Resection; Transplantation
Categories
Funding
- University of California San Francisco Liver Center [P30 DK-26743]
Ask authors/readers for more resources
Hepatocellular carcinoma is a leading cause of death in patients with cirrhosis. Management algorithms continually are increasing in sophistication and involve application of single and multimodality treatments, including liver transplantation, hepatic resection, ablation, transarterial chemoembolization, radioembolization, and systemic chemotherapy. These treatments have been shown to increase survival times. As many as 75% of patients with limited-stage disease who are given curative therapies survive 5 years, whereas less than 20% of untreated patients survive 1 year. Treatment can be optimized based on the patient's tumor stage, hepatic reserve, and functional status. However, because of the heterogeneity in presentation among patients, a multidisciplinary approach is required to treat hepatocellular carcinoma, involving hepatologists, surgeons, interventional radiologists, and oncologists. We present each specialist's viewpoint on controversies and advances in the management of hepatocellular carcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available